David W. Anderson

Dr. Anderson is an accomplished leader in medical research & product development with experience as a research scientist, director of research, entrepreneur, & executive leader in the pharmaceutical industry (Searle, Johnson & Johnson, Celgene), biotechnology (Signal/Celgene, Proprius Pharmaceuticals, Cypress Bioscience, Eclipse Therapeutics, and Ignyta), and several academic institutions (University of Colorado, The Scripps Research Institute, Graceland University). He holds a Ph.D. in Medical Microbiology and Immunology from the University of Missouri-Columbia.

He has a successful track record as a leader or member of teams responsible for development of 5 drugs (Procrit®, Leustatin®, & Revlimid® for oncology, Zubrin® for veterinary arthritis and Surfaxin® for respiratory distress syndrome), 9 INDs and multiple drug candidates. His expertise in Personalized Medicine in drug development (biomarkers, companion diagnostics) includes the launch of 2 products in a CLIA lab. David co-founded and was CSO/VP of R&D of Signal Pharmaceuticals (acquired by Celgene) and Proprius Pharmaceuticals (acquired by Cypress Bioscience) and help with 5 additional biotech start-ups.

Dr. Anderson has deep research experience/understanding of pathogenic processes, targets and unmet needs in oncology, inflammatory diseases, pain, bone diseases, virology, microbiology and metabolic diseases. David has held academic positions at the University of Colorado Health Sciences Center (Assistant Professor) and The Scripps Research Institution (Visiting Investigator). He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory and immunomodulatory drugs, and has refereed articles for peer-reviewed journals including Science and The Journal of Rheumatology. David also has an outstanding record of scientific publications and presentations (over 30 peer reviewed publications and 50 presentations/abstracts), been a member of AAI, ASCO, ACR and has received a number of awards and five patents for his innovative research.